reports
Veritas Pharma Inc: 1 director bought
A director at Veritas Pharma Inc bought 423,333 shares at 0.075CAD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
SYNL SYNALLOY CORP.
SREV SERVICESOURCE INTERNATIONAL INC.
SAR SARATOGA INVESTMENT CORP.
NFBK NORTHFIELD BANCORP INC.
LQDT LIQUIDITY SERVICES
CHCO CITY HOLDING COMPANY
MCY MERCURY NZ LTD.
KOPN KOPIN CORP.
TPL TEXAS PACIFIC LAND CORPORATION
MYOV MYOVANT SCIENCE
TURN 180 DEGREE CAPITAL
WTBA WEST BANCORP INC.
XERS XERIS PHARMACEUTICALS
A2PD39 VERITAS PHARMA INC
ULBI ULTRALIFE
NHS NEUBERGER BERMAN HIGH YIELD ST
MIDD THE MIDDLEBY CORPORATION
ANDE THE ANDERSONS
EVF INC.
VOXX EATON VANCE SENIOR INCOME TRUST
VVNT AUDIOVOX CORPORATION
VIVINT SMART HOME
INC.
Veritas Announces the Sale of the Sechelt Property
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - Veritas Pharma Inc.'s (CSE: VRT) (OTC: VRTHF) (Frankfurt: 2VP) ("Veritas" or the "Company") is pleased to announce that its fully owned subsidiary the Sechelt Organic Marijuana Corp. has completed the sale of its property located in Sechelt, BC, to Lis Holdings Ltd. for cash consideration of $350,000.This property was originally purchased in February 2015 with plans to construct a medical cannabis production facility under the ACMPR program. However, due to significant and unforeseen changes to the licensing requirements the pr...
Veritas Reaches a Mutual Settlement with Arbutus Biopharma Corporation
Veritas Reaches a Mutual Settlement with Arbutus Biopharma Corporation VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), is pleased to announce that it has reached a settlement with Arbutus Biopharma Corporation (“Arbutus”) with respect to the litigation commenced by Arbutus. The claims relate to a commercial lease space, which Veritas no longer believes is necessary for its R&D. As a part of the mutual settlement, no party has admitted any liability and there has not been any court finding a...
Veritas Announces the Sale of 3 Carbon Extractions Inc.
Veritas Announces the Sale of 3 Carbon Extractions Inc. VANCOUVER, British Columbia, July 10, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has completed the sale of its interest in 3 Carbon Extractions Inc. (“3 Carbon”) to Mr. Yari Nieken for cash consideration of $375,000. In April of 2018 Veritas Pharma announced the acquisition of 50% of the issued and outstanding shares of 3 Carbon. 3 Carbon is a private corporation that is in the business of designing cannabis extraction facilities and utilizin...
Veritas Announces Restructuring of Cannevert Therapeutics Ltd.
Veritas Announces Restructuring of Cannevert Therapeutics Ltd. VANCOUVER, British Columbia, May 15, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has undertaken steps to restructure and rebuild Cannevert Therapeutics Ltd. (“CTL”), a wholly owned subsidiary of Veritas. This restructuring includes both permanent and temporary cutbacks of the number of staff currently working with CTL with the exception of senior members of the research team. The company’s intention is to rehire several researchers on...
Veritas Announces the Completion of Clinical Trial on their Cannabis P...
Veritas Announces the Completion of Clinical Trial on their Cannabis Product for Treatment of Acute Pain SAN JUAN, Puerto Rico, May 15, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), is pleased to announce the completion of its clinical trial on its lead cannabis treatment (“CTL-X”) for acute pain. The clinical trial was designed as a randomized, double-blinded, cross-over trial and tested the efficacy of vaporized CTL-X for the treatment of acute pain in healthy adult subj...
Veritas Pharma Provides Corporate Update
Veritas Pharma Provides Corporate Update VANCOUVER, British Columbia, March 27, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce corporate highlights and to communicate the company’s direction for the year ahead. 2018 and the first quarter of 2019 has been a transition period for Veritas Pharma, as the company has matured from being purely engaged in research and development to establishing a viable option for cannabis production in Canada, setting the stage for potential commercialization given po...
UPDATE -- Veritas Pharma to Commence Legal Proceedings Against Liht Ca...
UPDATE -- Veritas Pharma to Commence Legal Proceedings Against Liht Cannabis VANCOUVER, British Columbia, March 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim and is commencing legal proceedings against Liht Cannabis Corp. ("Liht") (formerly Marapharm Ventures Inc.) to recover a loan made by Veritas to Liht in the amount of $1,000,000.00 plus accrued interest. The loan is in default and Veritas has made demand for repayment but Liht has refused to make repayment. About Veritas Ph...
Veritas Enrolls First Patient in Clinical Study to Assess Pain Control...
Veritas Enrolls First Patient in Clinical Study to Assess Pain Control with Lead Product SAN JUAN, Puerto Rico, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Rico LLC, a wholly owned subsidiary of Veritas Pharma, Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), today announced the dosing of the first adult volunteer in its clinical trial of their lead cannabis product (“CTL-X”) for the treatment of acute pain. The randomized, double-blinded crossover trial will assess the safety, tolerability and efficacy of CTL-X as a single dose vaporized challenge in 16 healthy ad...
Veritas Pharma Enters into agreement to acquire Commercial Hemp and Ca...
Veritas Pharma Enters into agreement to acquire Commercial Hemp and Cannabis Processing Facility VANCOUVER, British Columbia, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into an agreement with TG Initiatives Ltd., to purchase a commercial processing facility for hemp and cannabis products(“asset”), that asset is capable of making a variety of hemp and cannabis products including edibles for human and animal use. Additionally, this asset provides the capability to ma...
Veritas Pharma Announces the Resignation of CEO, Dr. Lui Franciosi
Veritas Pharma Announces the Resignation of CEO, Dr. Lui Franciosi VANCOUVER, British Columbia, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces the resignation of its President, CEO and Director, Dr. Lui Franciosi. Company Interim CFO, Mr. Peter McFadden will fill the executive roles in the interim until a qualified replacement is found. Dr. Franciosi stated, “It has been a challenging year with the regulatory delays in starting the Puerto Rico human study of CTL-X and the need to raise funds for med...
Veritas leads Puerto Rico partnership with approval of new Investigati...
Veritas leads Puerto Rico partnership with approval of new Investigation License SAN JUAN, Puerto Rico, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma, Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), in partnership with the Institute for Medical Cannabis (“IMC”) and the Fundación de Investigación (“FDI”) were approved this past Friday for an Investigation License from the Commonwealth of Puerto Rico Medicinal Cannabis Regulatory Board allowing clinical evaluation of their lead cannabis product (“CTL-X”) in allev...
Veritas Pharma to Proceed with Share Consolidation
Veritas Pharma to Proceed with Share Consolidation VANCOUVER, British Columbia, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it is proceeding with a consolidation of its issued and outstanding common shares at a ratio of one (1) post-consolidation common share for every ten (10) pre-consolidation common shares (the “Consolidation”) The common shares will commence trading on the Canadian Securities Exchange on a consolidated basis on February 11, 2019. The new CUSIP number will be 92347A205 and ...
Veritas Pharma Signs MOU with Santa Marta Gold Holdings for a Medical ...
Veritas Pharma Signs MOU with Santa Marta Gold Holdings for a Medical Cannabis Research Collaboration VANCOUVER, British Columbia, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with Santa Marta Gold Holdings Ltd. (“Santa Marta”) where both companies will share the intellectual property (“IP”) jointly developed as part of a proposed agreement that outlines a medical cannabis research collaboration. Under the terms of the MOU,...
Veritas Pharma Makes Strategic Investment in Cannabis Production for F...
Veritas Pharma Makes Strategic Investment in Cannabis Production for Future Cannevert R&D Needs VANCOUVER, British Columbia, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that the Company has entered into a share exchange agreement with three separate individuals for the issuance of 14,583,333, 14,583,333 and 12,500,000 common shares of Veritas at $0.12 per share in exchange for their 700,000, 700,000, and 600,000 shares at $2.50 per share, respectively, of the private cannabis growing c...
Veritas Appoints Corporate Secretary & CFO; and Issues Stock Options
Veritas Appoints Corporate Secretary & CFO; and Issues Stock Options VANCOUVER, British Columbia, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce the appointment of Blair Lowther as the Corporate Secretary of the Company. Blair is a corporate lawyer with many years of experience working with public companies, particularly in the cannabis industry. Blair is excited to help ensure the continued integrity of the Company’s governance framework, administration and regulatory compliance. Dr. Lui...
Veritas Announces Binding Share Purchase Agreement with Leis Industrie...
Veritas Announces Binding Share Purchase Agreement with Leis Industries Limited for Sale of Sechelt Organic Marijuana VANCOUVER, British Columbia, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into a binding share purchase agreement (the “Agreement”) to sell 100% of the outstanding common shares of Sechelt Organic Marijuana Inc. (“Sechelt”) to Leis Industries Limited (“Leis”). The Company previously announced on September 13, 2018 that it had entered into a Non-Bindin...
Veritas Confirms Readiness for Human Trials of CTL-X for Pain; Project...
Veritas Confirms Readiness for Human Trials of CTL-X for Pain; Projected to Start Early Next Month VANCOUVER, British Columbia, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that, despite the catastrophic events in Puerto Rico related to Hurricane Maria in the fall of 2017, and the restrictions imposed by US Federal Government’s conservative position on cannabis over the last year, it is now preparing to commence human trials to test its lead cannabis product (“CTL-X”). CTL-X is a uniqu...
Veritas Announces First Closing of Financing
Veritas Announces First Closing of Financing VANCOUVER, British Columbia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce the Closing of the Private Placement announced September 20, 2018. The Company was able to raise $1.56 million through the issue of 8,210,527 shares of common stock of the Company. The funds raised were used to acquire a 25% interest in a 10,000 square foot cannabis growing facility located in Kelowna British Columbia announced on October 25, 2018 for $1.25 million, an...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.